Thermo Fisher Scientific agreed to acquire Clario for about $9 billion, moving to integrate Clario’s clinical-trial software that captures, manages and analyzes endpoint data with Thermo Fisher’s existing clinical services. The deal, reported by MedCity News, pairs Clario’s cloud-based eClinical platform with PPD, the contract research organization Thermo Fisher bought in 2021. The acquisition aims to consolidate trial data collection and operations, accelerating end-to-end digital workflows for sponsors running global studies. Analysts view the move as a strategic push to control both logistics and the data layer of clinical development, potentially reducing trial timelines and costs. Thermo Fisher said the software is highly complementary to its existing biopharma services, though the transaction will invite integration and regulatory-compliance work across global trial operations.